Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Helmut Butzkueven; Stephanie Licata; Douglas Jeffery; Douglas L. Arnold; Massimo Filippi; Jeroen J.G. Geurts; Sourav Santra; Nolan Campbell; Pei‐Ran Ho

doi:10.1136/bmjopen-2020-038861

Back

Shared by

Massimo Filippi

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Article 2020 en

Authors

HB
Helmut Butzkueven
SL
Stephanie Licata
DJ
Douglas Jeffery

Abstract

1 min read

NCT02342704; EUCTR2013-004622-29-IT; Post-results.

Related publications

Article2018

086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study

Helmut Butzkueven, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Qunming Dong, Nolan Campbell, Stephanie Licata, Pei‐Ran Ho

Article2017

Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study

Stephanie Licata, Helmut Butzkueven, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Q. Dong, Nolan Campbell, Pei‐Ran Ho

Article2015

The Effects of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Relapsing Remitting Multiple Sclerosis: A One-Year Comparative Study (P6.152)

Paolo Preziosa, Maria A. Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Massimiliano Copetti, Lucia Moiola, Francesco Mele, Andrea Falini, Giancarlo Comi, Massimo Filippi

Article2017

The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study (P2.073)

Paolo Preziosa, Maria A. Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Lucia Moiola, Andrea Falini, Giancarlo Comi, Massimo Filippi

Article2024

Effects of fingolimod on focal and diffuse damage in patients with relapsing–remitting multiple sclerosis – The “EVOLUTION” study

Massimo Filippi, Elisabetta Pagani, Renato Turrini, Marta Bartezaghi, Vincenzo Brescia Morra, Giovanna Borriello, Valentina Torri Clerici, Massimiliano Mirabella, Livia Pasquali, Francesco Patti, Rocco Totaro, Paolo Gallo, Maria A. Rocca

Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

Abstract

Discussion(0)

Related publications

086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study

Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study

The Effects of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Relapsing Remitting Multiple Sclerosis: A One-Year Comparative Study (P6.152)

The Effects of Natalizumab and Fingolimod on Clinical and MRI Measures in Relapsing Remitting Multiple Sclerosis: A Two-Year Comparative Study (P2.073)

Effects of fingolimod on focal and diffuse damage in patients with relapsing–remitting multiple sclerosis – The “EVOLUTION” study